The association between cannabis use and psychiatric comorbidity in people with personality disorders: A population-based longitudinal study.


Journal

Psychiatry research
ISSN: 1872-7123
Titre abrégé: Psychiatry Res
Pays: Ireland
ID NLM: 7911385

Informations de publication

Date de publication:
08 2019
Historique:
received: 15 04 2019
revised: 25 05 2019
accepted: 25 05 2019
pubmed: 4 6 2019
medline: 31 3 2020
entrez: 2 6 2019
Statut: ppublish

Résumé

Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals with PDs who use cannabis are at increased risk for developing psychiatric disorders compared to cannabis users without a PD. Finally, we examined the interaction effect between cannabis use and personality disorders on comorbid psychiatric disorders. Data from 34,653 participants in waves 1 and 2 of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) were analyzed. Our findings indicate that individuals with PDs who used cannabis were at increased odds for developing substance use disorders (including opioid use disorder), but not other comorbid psychiatric disorders, at 3-year follow up. No significant interaction effects were generally found between cannabis use and PD. These findings suggest that aside from specific substance use disorders, individuals with PDs are not at an increased risk for developing other psychiatric disorders following cannabis use.

Identifiants

pubmed: 31153010
pii: S0165-1781(19)30866-2
doi: 10.1016/j.psychres.2019.05.041
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-77

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Nadav Shalit (N)

Lev-Hasharon Mental Health Center, Pardesiya, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: nadavs@lev-hasharon.co.il.

Jürgen Rehm (J)

Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada; Klinische Psychologie & Psychotherapie, Technische Universität Dresden, Dresden, Germany.

Shaul Lev-Ran (S)

Lev-Hasharon Mental Health Center, Pardesiya, Israel; Centre for Addiction and Mental Health, Institute for Mental Health Policy Research, Toronto, Ontario, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH